COMPANY OVERVIEW

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to ensure the best treatment outcome by optimizing patient adherence and improving the convenience and tolerability of drug therapies. We are addressing challenging diseases that require long-term chronic treatment by enhancing efficacy and reducing the burden therapies often place on the patient's life. Our drug development expertise and competitive edge are demonstrated by our ability to stabilize therapeutic proteins and peptides and to deliver them in a constant and consistent manner over an extended period of time via the unique and proprietary DUROS® drug delivery platform.

The DUROS implantable delivery technology has enabled Intarcia development programs in the areas of endocrinology and infectious diseases. Our most advanced programs are for the treatment of hepatitis C and type 2 diabetes both undergoing phase 1 clinical evaluation.

In addition to expanding our proprietary development programs, the DUROS technology holds broad potential applications for partnering opportunities with pharmaceutical and biotechnology companies in disease areas where poor patient tolerance to therapy and non-optimized treatment regimens represent significant obstacles to achieving treatment success.

Intarcia is privately held with its headquarters and manufacturing facilities in Hayward, CA.